2024
Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: the TRANSFORM-HF trial
Nouhravesh N, Clare R, Wojdyla D, Anstrom K, Velazquez E, Greene S, Pitt B, Mentz R, Psotka M. Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: the TRANSFORM-HF trial. European Heart Journal 2024, 45: ehae666.1068. DOI: 10.1093/eurheartj/ehae666.1068.Peer-Reviewed Original ResearchKCCQ-CSSTertile 1Diuretic doseHeart failureAll-cause mortalityTertile 3Tertile 2Diuretic strategyKansas City Cardiomyopathy Questionnaire Clinical Summary ScoreDoses of loop diureticsHigh doses of furosemideComposite all-cause mortalityBaseline to monthDose of furosemideClinical summary scoreRisk of adverse eventsInteraction p valuePost hoc analysisFurosemide equivalentsLoop diureticsOpen-labelMedian ageNo significant differenceClinical outcomesStudy endpointSacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure
Morrow D, Velazquez E, Desai A, DeVore A, Lepage S, Park J, Sharma K, Solomon S, Starling R, Ward J, Williamson K, Zieroth S, Hernandez A, Mentz R, Braunwald E. Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure. Journal Of The American College Of Cardiology 2024, 83: 1123-1132. PMID: 38508844, DOI: 10.1016/j.jacc.2024.01.027.Peer-Reviewed Original ResearchConceptsWorsening heart failureHeart failureEjection fractionNT-proBNPSpectrum of EFPIONEER-HFSpectrum of left ventricular ejection fractionRandomized trialsTime-averaged proportional changeN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideLeft ventricular ejection fractionWorsening heart failure eventDecompensated heart failureVentricular ejection fractionPlasma NT-proBNPPIONEER-HF trialDouble-blindMedian ageMedian EFSNatriuretic peptideSymptomatic hypotensionBaseline characteristicsClinical outcomesPooled analysisEfficacy And Safety Of Sacubitril/valsartan In Patients Hospitalized With Heart Failure: A Prespecified, Pooled Individual Patient-level Analysis Of PIONEER-HF And PARAGLIDE-HF
Morrow D, Velazquez E, Desai A, DeVore A, Lepage S, Park J, Sharma K, Solomon S, Starling R, Ward J, Williamson K, Zieroth S, Hernandez A, Mentz R, Braunwald E. Efficacy And Safety Of Sacubitril/valsartan In Patients Hospitalized With Heart Failure: A Prespecified, Pooled Individual Patient-level Analysis Of PIONEER-HF And PARAGLIDE-HF. Journal Of Cardiac Failure 2024, 30: 312-313. DOI: 10.1016/j.cardfail.2023.10.467.Peer-Reviewed Original ResearchSacubitril/valsartanPIONEER-HFHeart failurePooled analysisNT-proBNPControl therapyDe novo heart failurePlasma NT-proBNP levelsIndependent clinical events committeeIndividual patient-level analysisNovo heart failureNT-proBNP levelsClinical events committeePatient-level analysisCardiovascular deathHemodynamic stabilizationPrimary endpointSymptomatic hypotensionRenal functionMedian ageClinical outcomesRandomized trialsClinical effectsEvents committeeHF events
2023
Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial
Ghazi L, Yamamoto Y, Fuery M, O'Connor K, Sen S, Samsky M, Riello R, Dhar R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial. European Heart Journal 2023, 44: 4233-4242. PMID: 37650264, DOI: 10.1093/eurheartj/ehad512.Peer-Reviewed Original ResearchGuideline-directed medical therapyAcute heart failureMineralocorticoid receptor antagonistsHeart failureElectronic health recordsGDMT prescriptionPrimary outcomeEnzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitorsSodium-glucose cotransporter 2 inhibitorsAngiotensin receptor neprilysin inhibitorElectronic health record alertsEvidence-based regimenProviders of patientsReduced ejection fractionCotransporter 2 inhibitorsRelevant patient characteristicsTime of dischargePre-specified criteriaAHF hospitalizationEligible patientsInpatient initiationPatient characteristicsEjection fractionHospitalized patientsMedian ageCardiology Encounters for Underrepresented Racial and Ethnic Groups with Human Immunodeficiency Virus and Borderline Cardiovascular Disease Risk
Bloomfield G, Hill C, Chiswell K, Cooper L, Gray S, Longenecker C, Louzao D, Marsolo K, Meissner E, Morse C, Muiruri C, Thomas K, Velazquez E, Vicini J, Pettit A, Sanders G, Okeke N. Cardiology Encounters for Underrepresented Racial and Ethnic Groups with Human Immunodeficiency Virus and Borderline Cardiovascular Disease Risk. Journal Of Racial And Ethnic Health Disparities 2023, 11: 1509-1519. PMID: 37160576, PMCID: PMC10632543, DOI: 10.1007/s40615-023-01627-0.Peer-Reviewed Original ResearchBody mass indexCVD riskCardiovascular diseaseCVD risk factor managementCox proportional hazards regressionHigher body mass indexUrban residenceRisk factor managementCardiovascular disease riskHuman immunodeficiency virusProportional hazards regressionAssociation of patientHigh-risk individualsAcademic medical centerAmbulatory visitsMedian ageMass indexProvider factorsAtrial fibrillationHazards regressionImmunodeficiency virusResultsA totalFactor managementInsurance typeMedical CenterEffect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure
Mentz R, Anstrom K, Eisenstein E, Sapp S, Greene S, Morgan S, Testani J, Harrington A, Sachdev V, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Velazquez E, Adams K, Bhatt K, DeWald T, Axsom K, Murthy S, Rich J, Testani J, Smith B, Vader J, McCulloch M, Skopicki H, Psotka M, Heroux A, Lala-Trindade A, Stevens G, Tang W, Lev Y, William P, Eberly A, Gottleib S, Haught W, Grafton G, Larned J, Tejwani L, Mody F, Krim S, Robinson M, Fang J, Adler A, Bell A, Banerjee D, Ruiz Duque E, Mizyed A, Rommel J, Arhinful J, Goyal P, Hall M, Hummel S, Shetty S, Haas D, Vilaro J, Alexy T, Herre J, Clark J, Ambrosy A, Gaglianello N, Ramasubbu K, Meadows J, Tabtabai S, Sherwood M, Hasni S, D'Urso M, Muneer B, Dunlap S, Davis W, Friedman D, Guglin M, Ferguson A, Abbate A, Smart F. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure. JAMA 2023, 329: 214-223. PMID: 36648467, PMCID: PMC9857435, DOI: 10.1001/jama.2022.23924.Peer-Reviewed Original ResearchConceptsCause mortalityHeart failureTorsemide groupFurosemide groupTotal hospitalizationsCause hospitalizationEffects of torsemideDiuretic strategyPrespecified subgroupsSecondary outcomesEjection fractionMedian agePrimary outcomeHospitalizationMAIN OUTCOMEPatientsFurosemideMortalityMonthsTorsemidePrimary hypothesisSignificant differencesFinal dateOutcomesTrials
2018
Predictors and Changes in Cardiac Hemodynamics and Geometry With Transcatheter Aortic Valve Implantation
Alenezi F, Fudim M, Rymer J, Dunning A, Chiswell K, Swaminathan M, Bottiger B, Velagapudi P, Nicoara A, Kisslo J, Velazquez E, Vemulapalli S, Bloomfield GS, Samad Z. Predictors and Changes in Cardiac Hemodynamics and Geometry With Transcatheter Aortic Valve Implantation. The American Journal Of Cardiology 2018, 123: 813-819. PMID: 30598241, DOI: 10.1016/j.amjcard.2018.11.038.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve implantationAortic valve implantationLV ejection fractionAortic stenosisValve implantationEjection fractionLV massCardiac hemodynamicsBaseline LV ejection fractionLeft ventricle mass indexPost-TAVI paravalvular leakLV global longitudinal strainDuke University Medical CenterBaseline LV massLV mass regressionSevere aortic stenosisVentricle mass indexGlobal longitudinal strainTreatment of patientsUniversity Medical CenterGreat clinical successTAVI patientsReverse remodelingTransthoracic echocardiographyMedian ageTranscatheter Aortic Valve Replacement versus Medical Management among Patients with Aortic Stenosis and Left Ventricular Systolic Dysfunction
Lowenstern A, Vora A, Dunning A, Schulte P, Vemulapalli S, Hughes G, Velazquez E, Harrison J, Samad Z. Transcatheter Aortic Valve Replacement versus Medical Management among Patients with Aortic Stenosis and Left Ventricular Systolic Dysfunction. Structural Heart 2018, 2: 388-395. DOI: 10.1080/24748706.2018.1500049.Peer-Reviewed Original ResearchTranscatheter aortic valve replacementCoronary artery bypass graftSevere aortic stenosisVentricular systolic dysfunctionAortic valve replacementAortic stenosisMedical managementSystolic dysfunctionValve replacementOutcomes of patientsArtery bypass graftVentricular ejection fractionIschemic heart diseaseCause mortalityMultivariable adjustmentRenal insufficiencyTAVR patientsTransthoracic echocardiogramEjection fractionHeart failureMedian ageBypass graftHistorical cohortTherapeutic optionsPatient populationLiraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial
Sharma A, Ambrosy AP, DeVore AD, Margulies KB, McNulty SE, Mentz RJ, Hernandez AF, Felker G, Cooper LB, Lala A, Vader J, Groake JD, Borlaug BA, Velazquez EJ. Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. ESC Heart Failure 2018, 5: 1035-1043. PMID: 30120812, PMCID: PMC6300815, DOI: 10.1002/ehf2.12334.Peer-Reviewed Original ResearchConceptsWeight loss agentsHeart failureEjection fractionHF hospitalizationNew York Heart Association functional class IIIGlucagon-like peptide-1 (GLP-1) receptor antagonistHeart Failure Treatment studyWeight lossAcute HF hospitalizationEfficacy of liraglutideRecent HF hospitalizationFunctional class IIILast study visitReduced ejection fractionAdvanced heart failureCardiovascular outcome trialsMedian ejection fractionAnalysis of patientsLiraglutide useMultivariable adjustmentStudy drugObese patientsOutcome trialsMedian agePrimary outcome
2015
Temporal Trends in Disease Severity and Predicted Surgical Risk at the Time of Referral for Echocardiography in Patients Diagnosed with Aortic Stenosis
Ersboll M, Samad Z, Al Enezi F, Kisslo J, Schulte PJ, Shaw LK, Køber L, Harrison JK, Bashore T, Brennan M, Velazquez EJ. Temporal Trends in Disease Severity and Predicted Surgical Risk at the Time of Referral for Echocardiography in Patients Diagnosed with Aortic Stenosis. Critical Pathways In Cardiology A Journal Of Evidence-Based Medicine 2015, 14: 103-109. PMID: 26214813, DOI: 10.1097/hpc.0000000000000048.Peer-Reviewed Original ResearchConceptsSevere aortic stenosisProportion of patientsAortic stenosisSurgical riskHigh-risk aortic valve replacementDisease severityHealth care resource planningAortic valve replacementCalcific aortic stenosisHeart valve surgeryTime of referralTertiary hospital centerNumber of patientsNative aortic valveDuke University HospitalLogistic EuroSCOREValve surgeryValve replacementMedian ageReferral patternsUniversity HospitalAortic valveHospital CenterPatientsReferral
2006
Predicting significant coronary artery disease in patients with left ventricular dysfunction
Whellan DJ, Tuttle RH, Velazquez EJ, Shaw LK, Jollis JG, Ellis W, O'Connor CM, Califf RM, Borges-Neto S. Predicting significant coronary artery disease in patients with left ventricular dysfunction. American Heart Journal 2006, 152: 340-347. PMID: 16875920, DOI: 10.1016/j.ahj.2005.12.001.Peer-Reviewed Original ResearchConceptsSignificant coronary artery diseaseCoronary artery diseaseSegmental wall motion abnormalitiesLeft ventricular dysfunctionWall motion abnormalitiesEjection functionCardiac catheterizationVentricular dysfunctionArtery diseaseMedian ageMotion abnormalitiesLikelihood of CADAccurate baseline assessmentPatients' median ageMajor epicardial vesselsDiagnostic cardiac catheterizationNumber of patientsUnnecessary invasive proceduresStepwise logistic regressionClinical characteristicsEchocardiographic parametersPrevalent comorbiditiesDuke DatabankHeart failureDiabetes mellitus